Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PDL BioPharma has reported a net income of $48.57m, or $0.32 per diluted share, for the third quarter ended 30 September 2012 compared to $45.92m, or $0.28 per diluted share, for the third quarter ended 30 September 2011.
Subscribe to our email newsletter
Total revenues for third quarter of 2012 were $85.23m compared to $83.77m for the third quarter of 2011.
The company reported a net income of $162.26m, or $1.08 per diluted share, for the nine months ended 30 September 2012 compared to a net income of $160.45m, or $0.88 per diluted share, for the nine months ended 30 September 2011.
Total revenues of $288.48m were reported for the first nine months of 2012 compared to $289.23m for the first nine months of 2011.
PDL BioPharma has announced that the increase in royalty revenues by 2% are based on second quarter 2012 product sales by its licensees.